ALK and non-small cell lung carcinoma: A retrospective analysis of patients with EGFR-mutated and ALK-rearranged NSCLC receiving SRS for four or more BrMs found that the mean hippocampal (1.2 Gy) and whole-brain (0.8 Gy) doses remained low with SRS for more than ten lesions [56].